Nektar Therapeutics (NKTR) - Stock Analysis

Last updated: Mar 9, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Nektar Therapeutics benefits from positive Phase 2b results in atopic dermatitis and upcoming data releases (alopecia areata Dec 2025, atopic dermatitis Q1 2026) with strong cash runway into mid-2027. Technical momentum and supportive biotech sector elevate NKTR as a hot near-term idea with significant catalyst-driven upside potential.

Loading chart data...

Idea window: 12/1/2025 – 12/8/2025Sector: Healthcare

AI Analyst Overview

Last Price

$73.25

Market Cap

$1.49B

1D Return

+4.11%

YTD Return

+73.25%

Loading chart data...

Valuation Metrics

P/E

-9.1

P/B

17.5

P/S

27.0

EV/EBITDA

-11.3

Div Yield

—

Fundamental Analysis

6.0

Key Financial Insights: • Strong liquidity • Negative FCF • High R&D expense NKTR has strong short‑term liquidity and sizable investments supporting obligations, but deteriorating operating results, negative free cash flow and inconsistent market/valuation figures create significant execution and valuation risk.

Liquidity

Losses

Price Behavior

7.0

Key Price Behavior Insights: • Strong uptrend • Resistance test • High volatility Support Level: $68–$70 (short-term); long-term base $35–$40 Resistance Level: $73.6–$73.9 Over the last month NKTR roughly doubled from the mid-$30s to the low-$70s, showing strong momentum but stalling at $73.6–$73.9 with high volatility and elevated pullback risk.

momentum

risk

Sentiment & News

7.0

Key News Insights: • Catalyst‑driven rally • Large equity raise • Elevated trading/flow Positive Phase 2b data plus a $460M equity raise and heavy trading/analyst upgrades drove a dramatic stock rally despite expected near‑term earnings weakness.

Nektar

Rezpegaldesleukin

AI Summary

6.0

Neutral

NKTR is effectively a single‑asset, event‑driven biotech where REZPEG's Phase‑III results and CMC/commercial readiness will determine whether the recent $460M equity raise converts into a high‑upside commercial story or triggers severe value compression. Monitor three actionable checkpoints—pivotal EASI‑75 durability/safety readout, on‑time CMC scale‑up with acceptable unit economics, and monthly burn vs. plan—to gauge whether to hold for upside or prepare for dilution-driven downside.

REZPEG

CMC

FDA

AI summary updated 6 days ago

Description

Nektar Therapeutics is a biopharmaceutical company that develops therapies for oncology and immune-mediated diseases, with a portfolio spanning late-stage and earlier-stage clinical programs. Its pipeline includes a late-stage interleukin-2 pathway candidate for several solid tumors and multiple cytokine and immune-modulating programs in earlier trials. The company maintains partnerships with a range of large pharmaceutical firms and is headquartered in San Francisco; it was incorporated in 1990.

Idea History

Date	Close	Ticker	Company	Summary	Status	P/L
Dec 1	Dec 8	NKTR	Nektar Therapeutics	Nektar Therapeutics benefits from positive Phase 2b results in atopic dermatitis and upcoming data releases (alopecia areata Dec 2025, atopic dermatitis Q1 2026) with strong cash runway into mid-2027. Technical momentum and supportive biotech sector elevate NKTR as a hot near-term idea with significant catalyst-driven upside potential.	Closed	-6.3%

People also watch

Fortrea Holdings Inc.

FTRE

+7.2%

TransMedics Group, Inc.

TMDX

-4.2%

Phibro Animal Health Corporation

PAHC

+12.8%